Companies launch co-development in bid to stop heart attacks and save lives

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Hypertension Blood pressure Heart health Technology cardiovascular health Research

TechBio company, Closed Loop Medicine Ltd, and pharmaceutical company, Pharmanovia have entered into a co-development for precision medicine combination therapeutics.

Closed Loop develops combination prescription drugs and software therapy products that they say enables personalized dose optimization, while Pharmanovia commercializes new medicines and revitalizes, expands the lifecycle of established medicines. The companies made the announcement yesterday (May 17).  

The companies announced that they will initially focus on the development, and launch, of a drug plus software combination version of a first-line anti-hypertensive in the UK, before a 'phased global roll-out' and additional therapies are added.

During their research the companies found that hypertension is the leading preventable cause of morbidity and premature death worldwide, impacting over 1 in 4 men and 1 in 5 women, and costing the NHS alone over £2.1 billion/year.

Improved standards of care saves lives 

They said managing high-blood pressure through medication and lifestyle modifications significantly reduces associated health risks and improves quality of life; research in the US demonstrating improved standards of care could prevent 91,900 heart attacks, 139,000 strokes and 115,400 cardiovascular deaths within just five years.

However, they also found that poor drug tolerability and treatment-related side effects significantly impact adherence, with, they say, less than 50% of patients maintaining their treatment regimen after a year, ultimately hindering treatment effectiveness, patient outcomes and overall disease management.

James Burt, CEO of Pharmanovia, said: “Combining our experience in lifecycle management with Closed Loop Medicine’s unique approach and technology is an exciting next step in our strategy. It enables us to use innovative technology to enhance established medicines and bring much needed innovation to an area of large-scale unmet need.

"Together we aim to deliver a first in class combination regulated software and medicine – with the aim of delivering better patient outcomes, while enabling healthcare systems to reduce costly hospital procedures through better adherence and patient engagement.”

As part of this partnership, Closed Loop Medicine’s proprietary Software-as-a-Medical Device (SaMD) dosing optimization technology will be combined with Pharmanovia’s established anti-hypertensive medicines, under a single prescription.

Technology will dose optimize drug therapy

Closed Loop Medicine says its recent preliminary clinical trial results have demonstrated that its technology may provide the ability to dose optimize drug therapy, improve blood pressure control, and minimize side effects. By developing a new class of combination products for the treatment of hypertension, both companies aim to support patients and healthcare professionals to better manage high blood pressure.

Hakim Yadi OBE, CEO & co-founder of Closed Loop Medicine, said: “This pioneering partnership is a great example of where the power of software integration can add value to iconic medicines to make them more effective for patients.

“Through this co-development agreement, we will bring our IP, insight and technical know-how of dose optimized drug plus software integration alongside Pharmanovia’s innovative business model, to enable well-known and trusted brands to be positioned as value-driven precision medicine product solutions globally.”

Related topics Contract Manufacturing & Logistics

Related news

Show more

Follow us

Webinars

Headlines